Overview
ABVX market data
Price History
ABVX price chart · 1M
- O
- 112.45
- H
- 116.04
- L
- 112.20
- C
- 114.04
- Vol
- 70,933.00
- Source
- US equities market feed
- Observed
- Sep 3, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $112.45
- Previous Close
- $111.18
- Day High
- $116.04
- Day Low
- $112.20
- 52 Week High
- $147.87
- 52 Week Low
- $69.91
- 7 Day Return
- -0.30%
- 30 Day Return
- -8.91%
- 90 Day Return
- +12.28%
- 1 Year Return
- -8.52%
- Daily Notional Volume
- $8.1M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$4.83 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.73 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -50,800.0% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $60.45 – $139.00 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $8.4B · P/B 19.86.
Company News
10 captured
Abivax Completes Pre-New Drug Application Interaction For Obefazimod With FDA To Treat Adults With Moderately To Severely Active Ulcerative ColitisBenzinga · Jul 30, 2026, 8:18 PM
Palisade Bio Analyst Sees Lead Drug Can Potentially Bridge Gap in Ulcerative ColitisBenzinga · Jul 23, 2026, 6:06 PM
'Biotech Abivax re-engages investment bank Centerview for Big Pharma takeover talks' - La LettreBenzinga · Jul 17, 2026, 6:04 PM
Piper Sandler Maintains Overweight on Abivax, Raises Price Target to $175Benzinga · Jul 9, 2026, 4:05 PM
Truist Securities Maintains Buy on Abivax, Raises Price Target to $155Benzinga · Jul 2, 2026, 11:50 AM
Citizens Reiterates Market Outperform on Abivax, Maintains $187 Price TargetBenzinga · Jul 1, 2026, 1:50 PM
Abivax announces trading resumption of its ordinary shares on Euronext ParisGlobenewswire Inc · Jul 1, 2026, 1:15 PM
Abivax Announces Pricing Of Underwritten Public Offering Of 6.40M ADSs At $125.00 EachBenzinga · Jul 1, 2026, 12:45 PM
Jefferies Upgrades Abivax to Buy, Raises Price Target to $158Benzinga · Jun 30, 2026, 8:20 PM
Nasdaq Gains Over 300 Points; Chicago PMI Falls In JuneBenzinga · Jun 30, 2026, 4:10 PM